I graduated with a BSc (Hons) from the University of Melbourne. I undertook my PhD at the St Vincent’s Institute (Melbourne), where I studied the development and function of islet-specific T cells in autoimmune diabetes. I was also part of the Tom Mandel Islet Transplantation Programme, which offered access to islet transplantation for people with type 1 diabetes. After successfully completing my PhD, I joined the National Centre of Asbestos Related Disease (NCARD) in November 2014, and am currently a Cancer Council Western Australia Postdoctoral Fellow. 

My research interests are in understanding the immunology mechanisms that underlie why some mesothelioma patients respond better to immunotherapy/chemotherapy but not others. The end goal is to utilise this knowledge to develop novel therapies and accurate predictors of treatment outcomes. I am particularly interested in understanding how the T cell repertoire influences treatment outcomes in cancer patients. 

1. The integration of mathematics and TCR sequencing to understand how an individual’s immune system contributes to therapy success
2. The development of preclinical models to study why some patients develop severe autoimmunity after cancer immunotherapy
3. The development of novel epigenetic targeting tools to improve mesothelioma therapy outcomes

• Lead the murine TCR, mesothelioma-epiCRISPR and irae projects at NCARD
• Manage and maintain preclinical models at NCARD 
• Supervision of PhD and Honours students

 Tumour Immunology Lecture

"Vaccines to immune checkpoint blockade" PATH3309 

English, Mandarin